Genmab A/S, a leading biotech company based in Denmark with its shares listed on NASDAQ- GMAB, recently made several significant decisions influencing its stock value. The company has made notable strides with
FDA approvals, raising share targets twice. The analysts at
HC Wainwright reaffirmed their buy rating on Genmab, while
BTIG Research raised its price target to $47.00. There seems to be a consensus Hold rating amongst analysts. Concurrently,
Genmab advanced its
share buy-back program and successfully completed it, which was followed by share capital expansion plans. Additionally,
ProfoundBio, an ovarian cancer drug developer, was acquired by Genmab for $1.8 billion. Several investment giants like
Park Avenue Securities LLC,
Goldman Sachs Group Inc., and
Wellington Management Group LLP sold substantial shares of Genmab, while others like
GAMMA Investing LLC and
Harding Loevner LP increased their holdings. Despite hitting a new 52-week low at $24.94, the company`s EPKINLY® gained FDA approval for lymphoma treatment, indicating continued progress in drug R&D. Genmab finished Q1 2024 with strong Darzalex sales but faced a setback with disappointing lung cancer drug data in partnership with Johnson & Johnson.
Genmab Stocks News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 30 Jun 2024 09:11:40 GMT -
Rating -2
- Innovation 3
- Information 7
- Rumor -3
